Antithrombin-III for New Coronavirus Infection (COVID-19) Under Conditions of Extracorporeal Membrane Oxygenation (Clinical Observation)

S. V. Zhuravel, V. V. Vladimirov, P. V. Gavrilov, I. V. Ivanov, S. S. Petrikov, K. A. Popugayev,A. M. Talyzin

Neotložnaâ Medicinskaâ Pomoŝʹ(2022)

引用 0|浏览2
暂无评分
摘要
COVID-19 is a disease that, in addition to respiratory failure, leads to thrombosis and bleeding due to coagulation disorders. Extracorporeal membrane oxygenation (ECMO), required in cases of a deterioration of gas exchange function of the lungs, contributes to changes in blood coagulation indicators, which leads to an increased risk of hemorrhagic complications and thrombosis. In the article, a clinical case of a severe course of COVID-19 is reported, which required ECMO. During the treatment, antithrombin-III was used, which allowed avoiding life-threatening complications and successfully completing the procedure.
更多
查看译文
关键词
covid-19,sars-cov-2,ecmo,thrombosis,bleeding,antithrombin,heparin,anticoagulant therapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要